Biophysical defects of an SCN5A V1667I mutation associated with epinephrine-induced marked QT prolongation.
Tadashi NakajimaTommy DharmawanReika Kawabata-IwakawaShuntaro TamuraHiroshi HasegawaTakashi KobariYoshiaki KanekoMasahiko NishiyamaMasahiko KurabayashiPublished in: Journal of cardiovascular electrophysiology (2020)
We demonstrated an increase of V1667I-INa by PKA activation, which may provide a rationale for the efficacy of β-blocker therapy in some cases of LQT3.